Professor Richard Gilbertson MBBS, PhD
Click here to find out more
This March, we're bringing you a rare and unique opportunity to get your research questions answered. Our Scientific Advisory Board is coming together from across the globe to update you on brand new, innovative research and answer your questions.
So, if you find it hard to wrap your head around the role of genetics, want to know more about symptom management, or would like to learn more about how new therapies are developed and their pathway to public access, then this is the event for you!
On Tuesday 6 March, 7pm-9pm, four internationally renowned brain tumour experts will be joining us at King's College London, Waterloo Campus, to present their research, giving you an exclusive insight into what they're currently working on. The floor will then be opened for you, the audience, to ask these knowledgeable experts any questions you have about research, clinical trials, drug pathways, and much more!
The event will also be hosted by ITV news journalist and OBE, Alastair Stewart, who has a personal connection to The Charity and is a well-respected newscaster with decades of experience.
When: Tuesday 6 March 2018, 7pm-9pm, doors at 6:40pm for a prompt 7pm start
Where: King's College London, Franklin Wilkins Building, Waterloo Campus, 150 Stamford St, Lambeth, London SE1 9NH
Tickets: £5 per person
Professor Richard Gilbertson is one of the world's leading experts in childhood brain tumours. He is currently the Director of the Cancer Research UK Cambridge Centre at Cambridge University and has been working in paediatric oncology as both a clinician and a researcher for almost 25 years.
His work has helped identify different subtypes of medulloblastoma and ependymoma – two of the most common types of childhood brain tumour. This has been translated into numerous diagnostic tests and innovative clinical trials for children with brain tumours.
Professor Gilbertson's dedication to conducting research to understand more about childhood brain tumours continues to shed light on the differences between the subtypes of medulloblastoma and ependymoma, which is vital to improve the diagnosis and treatment of brain tumours.
Dr Paul Northcott is a leading paediatric cancer genome scientist. The Northcott lab is interested in solving the molecular and cellular origins of medulloblastoma (a childhood brain tumour). Combining cutting-edge, next-generation sequencing and integrative computational approaches with in vivo functional studies, they aim to comprehensively understand the genetic, epigenetic, and transcriptional landscapes underlying medulloblastoma.
Dr Northcott's novel and innovative work is helping us understand the role of genetics in tumour development, and bringing us closer to new and better treatments that can slow tumour growth.
Dr Mark Gilbert is the founder and former leader of the Collaborative Ependymoma Research Network (CERN), a group studying ependymoma tumours by supporting basic research, clinical trials, patient outcomes research and educational efforts in North America and Europe.
Dr Gilbert's interests lie in developing new treatment strategies for patients with malignant primary brain tumours. His focus has been in the area of clinical research, emphasising large, multi-institutional studies for malignant gliomas, as well as smaller clinical trials to advance therapies for less common cancers. His vision is to build a highly collaborative research programme centred on finding treatments for brain tumours, where basic research observations will be rapidly translated into pre-clinical testing.
Dr Terri Armstrong is a senior investigator at the National Institute of Health in the USA, and vice president of the Society of Neuro-Oncology, an international multidisciplinary organisation for those involved in research and care of neuro-oncology patients.
Dr Armstrong has worked in the field of neuro-oncology since 1992, with her primary aim being to improve quality of life for both adult and paediatric patients. Her program of research focuses on clinical outcomes assessment in clinical trials, exploring the biological basis of symptoms and toxicity and developing better interventions for symptom management.